




IPW:

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	10/675,971
	Filing Date	October 2, 2003
	First Named Inventor	Peter DiBenedetto
	Art Unit	3738
	Examiner Name	Not Yet Assigned
Total Number of Pages in this Submission	Attorney Docket Number	5118

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below):
<b>Remarks</b> Form 1449 Copies of 15 References Copy of International Search Report Postcard		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm	GENZYME CORPORATION		
Signature			
Printed Name	Robert J. Cobert		
Date	24 March 05	Reg. No.	36,108

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Signature			
Typed or printed name	Carol S. Celata	Date	3/24/2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

FIRST NAMED INVENTOR:	SERIAL NO:	FILING DATE	ART UNIT:	CONFRM NO.
Peter DiBenedetto	10/675,971	October 2, 2003	3738	7789
<b>TITLE:</b>			<b>EXAMINER:</b>	
Assays For Evaluating Anti-Osteoarthritic Activity			Not Yet Assigned	

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**INFORMATION DISCLOSURE STATEMENT**

This Information Disclosure Statement herewith is being filed before the mailing of a first Office Action on the merits.

Applicant submits form PTO-1449 for consideration under CFR § 1.97(b) along with copies of the references listed #1-15

Certain of the listed references were cited in the International Search Report dated December 27, 2004 issued in the corresponding PCT application (copy attached herewith).

Applicant believes that no fee is due with this submission.

However, if any fees are required, the Commissioner is authorized to charge the said fees to Deposit Account No. 07-1074.

Respectfully submitted,

Robert J. Cobert  
Attorney for Applicant  
Registration No. 36,108

Date: -March 24, 2005

GENZYME CORPORATION  
Legal Department  
500 Kendall Street  
Cambridge, Massachusetts 02142  
Tel. (617) 768-6823  
Fax. (617) 252-7553

Under the Paperwork Reduction Project  
Form 1440-1000

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449-A-90

***(Use as many sheets as necessary)***

Sheet	1	of	2
-------	---	----	---

**Complete if Known**

<i>Application Number</i>	10/675,971
<i>Filing Date</i>	October 2, 2003
<i>First Named Inventor</i>	Peter DiBenedetto
<i>Art Unit</i>	3738
<i>Examiner Name</i>	Not Yet Assigned
<i>Attorney Docket Number</i>	5118

[illegible][illegible]

**Examiner  
Signature**

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>		
		Application Number	10/675,971	
		Filing Date	October 2, 2003	
		First Named Inventor	Peter DiBenedetto	
		Art Unit	3738	
		Examiner Name	Not Yet Assigned	
Sheet	2	2	Attorney Docket Number	5118

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	6	HASCALL et al., "The Effect of Serum on Biosynthesis of Proteoglycans by Bovine Articular Cartilage in Culture", <i>Archives of Biochemistry and Biophysics</i> , Vol. 224, No. 1 pp. 206-223 (1983)	
	7	AYDELOTTE, et al. "Articular Chondrocytes Cultured in Agarose Gel for Study of Chondrocytic Chondrolysis", <i>Articular Cartilage Biochemistry</i> , pp. 235-256 (1986)	
	8	MUIR, et al., "Effects of Tiaprofenic Acid and Other NSAIDs on Proteoglycan Metabolism in Articular Cartilage Explants", <i>Drugs</i> , Vol. 35 (Suppl. 1), pp 15-23 (1988)	
	9	KOLIBAS et al., "Effect of cytokines and anti-arthritis drugs on glycosaminoglycan synthesis by bovine articular chondrocytes", <i>Agents and Actions</i> , Vol. 27, ¾ pp. 245-249 (1989)	
	10	ARSENIS et al., "Effects of antirheumatic drugs on the interleukin-1 $\alpha$ induced synthesis and activation of proteinases in articular cartilage explants in culture", <i>Agents and Actions</i> , Vol. 27, ¾ pp. 261-264 (1989)	
	11	GUO et al., "Culture and Growth Characteristics of Chondrocytes Encapsulated in Alginate Beads", <i>Connective Tissue Research</i> , Vol. 19, pp. 277-297 (1989)	
	12	BOYLE et al., "Characterization of proteoglycan accumulation during formation of cartilaginous tissue <i>in vitro</i> ", <i>Osteoarthritis and Cartilage</i> , Vol. 3, pp. 117-125 (1995)	
	13	TUBO et al., "Articular Cartilage", <i>Human Cell Culture</i> , Vol. V, pp. 1-16 (2001)	
	14	ADCOCKS, et al., "Catechins from Green Tea ( <i>Camellia sinensis</i> ) Inhibit Bovine and Human Cartilage Proteoglycan and Type II Collagen Degradation <i>In Vitro</i> <sup>1,2</sup> ", <i>Journal of Nutrition</i> , Vol. 132, No. 3, pp. 341-346 (2002)	
	15	CURTIS et al., "The Effect of n3 (Omega-3) Polyunsaturated Fatty Acids on Degenerative Joint Disease", <i>Agro Food Industry Hi-Tech</i> , Vol.14, No. 3 pp. 22-25 (2003)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.